Search results
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 5 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
Unknown risk factor linked to high rates of kidney cancer, DNA study finds
Medical Xpress· 5 days agoIn a paper published in Nature, scientists from the Mutographs Cancer Grand Challenges team, based at the Wellcome Sanger Institute, the International Agency for Research on Cancer, and a large ...
Good to Know: Grim diagnosis spurs Kent couple to sell possessions, plan RV trip of a lifetime
Akron Beacon Journal· 19 hours agoPlan B moves to the top of the list for Mark Dailey and Melissa Cairns after cancer diagnosis. The...
HC Wainwright Reaffirms Buy Rating for Exelixis (NASDAQ:EXEL)
ETF DAILY NEWS· 21 hours agoHC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report sent to investors on Friday, Benzinga reports. Several other equities analysts ...
Sutent Dosage: Form, Strengths, How to Take, and More
Healthline· 6 days agoSutent is a prescription drug used to treat certain types of cancer. Learn about the drug's dosages, form, strengths, how to take it, and more.
Headlands Technologies LLC Has $32,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 4 days agoHeadlands Technologies LLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 70.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,341 shares of the biotechnology ...
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Benzinga· 6 days agoDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20 TherapiesCD 70
Retirement Systems of Alabama Sells 8,056 Shares of Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 4 days agoRetirement Systems of Alabama cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure ...
New York State Common Retirement Fund Sells 5,141 Shares of Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 4 days agoNew York State Common Retirement Fund trimmed its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 0.5% during the 4th quarter, according to the company in ...
Short Interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Rises By 5.6%
ETF DAILY NEWS· 5 days agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 48,980,000 shares ...